Company Overview of MIGENIX Corp.
MIGENIX Corp. provides research and development services for drugs used in the treatment of medical conditions related to mitochondrial dysfunction. The company has clinical and preclinical product candidates for neurological, metabolic, and degenerative diseases. The company develops MITO-4509 for Alzheimer’s disease; MITO-4565 for Glaucoma; and MITO-4042 for Arthritis. The company formerly known as Mitokor, Inc. and changed its name to MIGENIX Corp. in September 2004. The company was founded in 1991 and is based in San Diego, California. As of August 31, 2004, MIGENIX Corp. operates as a subsidiary of Metro Vancouver Properties Corp.
11494 Sorrento Valley Road
San Diego, CA 92121
Founded in 1991
Key Executives for MIGENIX Corp.
MIGENIX Corp. does not have any Key Executives recorded.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact MIGENIX Corp., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.